Santhera Closes License-Back Deal with Takeda For European Rights to Catena in Duchenne Muscular Dystrophy

06-Sep-2013 - Switzerland

Seamlessly Digitize Your Quality Management

ASKION FluoS - The platform for entry level automated fluorescence microscopy

Santhera Pharmaceuticals announced that it reached an agreement with Takeda to license back previously granted European rights to Catena^® (INN: idebenone) in Duchenne muscular dystrophy (DMD). In a back-loaded deal, Santhera regains European commercialization rights for Catena^®. The drug is currently being investigated in a Phase III study in DMD conducted in Europe and in the USA.

In 2007, Takeda Pharmaceutical Company Limited acquired the exclusive marketing rights in Europe and Switzerland for Catena^®for the treatment of DMD. Under the agreement Santhera licenses back all such previously granted rights to increase its strategic flexibility. In return, Takeda is eligible to obtain a percentage from future licensing and/or sales income generated by Santhera in DMD. In addition, Santhera has obtained the right to cross-reference Takeda's idebenone data for regulatory use in any indication in any territory. If Santhera makes use of such cross-reference right, Takeda is eligible to obtain a percentage from future licensing and/or sales income generated by Santhera in such indications. Lastly, both companies agreed to terminate a similar agreement for Friedreich's Ataxia signed in 2005 and Santhera's previously disclosed contingent liability of EUR 1 million payable to Takeda has been waived. Takeda is eligible to receive Euro 1 million as a percentage from future income generated by Santhera to offset this waiver.

https://www.bionity.com/en/news/144839/santhera-closes-license-back-deal-with-takeda-for-european-rights-to-catena-in-duchenne-muscular-dystrophy.html